The Oncology Institute, Inc. (NASDAQ:TOI) Director Sells $232,788.20 in Stock

The Oncology Institute, Inc. (NASDAQ:TOI - Get Free Report) Director Growth I. L.P. M33 sold 76,324 shares of the stock in a transaction that occurred on Thursday, June 5th. The shares were sold at an average price of $3.05, for a total transaction of $232,788.20. Following the sale, the director now directly owns 1,272,724 shares of the company's stock, valued at approximately $3,881,808.20. This represents a 5.66% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Oncology Institute Trading Down 7.3%

NASDAQ TOI traded down $0.21 on Thursday, hitting $2.65. 1,305,964 shares of the company were exchanged, compared to its average volume of 1,009,592. The company has a debt-to-equity ratio of 5.91, a current ratio of 2.49 and a quick ratio of 2.27. The Oncology Institute, Inc. has a twelve month low of $0.13 and a twelve month high of $3.50. The firm has a market capitalization of $236.47 million, a P/E ratio of -3.40 and a beta of 0.13. The company's 50 day moving average price is $2.59 and its 200-day moving average price is $1.31.

Oncology Institute (NASDAQ:TOI - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($0.18) earnings per share for the quarter. The firm had revenue of $104.41 million during the quarter. Oncology Institute had a negative return on equity of 186.83% and a negative net margin of 17.63%.

Institutional Trading of Oncology Institute

Several large investors have recently added to or reduced their stakes in TOI. Tiff Advisory Services LLC boosted its position in shares of Oncology Institute by 13.2% in the fourth quarter. Tiff Advisory Services LLC now owns 2,979,141 shares of the company's stock worth $921,000 after buying an additional 346,256 shares during the period. Josh Arnold Investment Consultant LLC acquired a new position in Oncology Institute during the first quarter valued at $2,267,000. FreeGulliver LLC lifted its stake in Oncology Institute by 219.3% in the 4th quarter. FreeGulliver LLC now owns 600,747 shares of the company's stock worth $186,000 after acquiring an additional 412,578 shares in the last quarter. Renaissance Technologies LLC boosted its position in Oncology Institute by 7.1% during the 4th quarter. Renaissance Technologies LLC now owns 182,000 shares of the company's stock worth $56,000 after acquiring an additional 12,000 shares during the period. Finally, Virtu Financial LLC acquired a new stake in Oncology Institute during the 4th quarter worth about $41,000. 36.86% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, BTIG Research began coverage on Oncology Institute in a research report on Thursday, May 15th. They set a "buy" rating and a $7.00 target price on the stock.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.